Source: RegeneRx Biopharmaceuticals, Inc.
Posted: 23 Nov 2006 - 12:00pm (PST)
Summary:
REGENERX BIOPHARMACEUTICALS, INC. (AMEX: RGN) (http://www.regenerx.com/) report that a study published in the advanced online edition of the journal Nature supported and elaborated TB4's significant effects in the damaged hearts of mice and highlighted its therapeutic potential for the treatment of heart attacks and heart failure in humans.
Commentary: Maybe these results will lead to human clinical trials of TB4 for heart attacks and heart failure patients.
No comments:
Post a Comment